We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Genetic Test Improves Noonan Syndrome Diagnosis

By LabMedica International staff writers
Posted on 11 Jul 2012
Print article
A new one-step test provides large-scale parallel screening of all 12 genes associated with Noonan disorders in one panel. This includes all coding exons of 11 genes plus exon 2 of SHOC2.

Molecular testing company NewGene (Newcastle-Upon-Tyne, United Kingdom) developed the new test in collaboration with the South West Thames Regional Genetics Service at St George’s Healthcare NHS Trust (Tooting, United Kingdom).

Noonan Syndrome and related disorders (rasopathies) are autosomal dominant congenital syndromes. These disorders are characterized by facial dysmorphism, a wide spectrum of cardiac disease, postnatal reduced growth, ectodermal and skeletal defects, and variable cognitive deficits.

Variable presentations of the syndrome make it difficult to provide a definitive clinical diagnosis. Correctly identifying the disorder is essential to ensure that appropriate care and monitoring is provided and to preclude unnecessary investigations.

Multiple samples with known mutations previously identified by the Sanger sequencing technique have been run alongside normal control samples in blind screening trials to validate the new sequencing assay.

The research laboratories at St George’s have worked for over 10 years to clone the genes for Noonan Syndrome. Currently genetic testing of suspected Noonan cases is carried out on a gradual basis by testing for one disorder or gene and then another until a mutation is identified to confirm the diagnosis. This is both time consuming and costly and delays the determination of the best clinical care pathway for patients.

Before the availability of molecular testing, making a clinical diagnosis was difficult and required many specialist tests including clotting and cardiac investigations. Molecular testing has simplified the process of making a diagnosis. However, due to the significant clinical overlap of the Noonan spectrum disorders, targeting the correct genes has remained problematic.

A positive test result will provide a definite diagnosis of the syndrome in question as the mutation spectrum has been well defined and no cases of nonpenetrance have been identified. Importantly, as a positive result will also determine which disorder is applicable, medical interventions appropriate for that specific disorder can be highlighted more quickly.

Professor Michael Patton, medical advisor for the Noonan Syndrome Association, UK, said, “Since the discovery of new genes in the RAS MAPK pathway it has become increasingly difficult and expensive to undertake full genetic testing for Noonan syndrome, but the development of the next generation sequencing test at NewGene and St George’s hospital is a major advance in the diagnosis of Noonan syndrome.”

Related Links:

NewGene
South West Thames Regional Genetics Service at St George’s Healthcare NHS Trust


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.